大剂量吉西他滨膀胱灌注化疗对膀胱非肌层浸润性尿路上皮癌复发率的影响

张卓　　张文圣　　万滨　　卢依刚　　李勋钢

[關键词] 大剂量;吉西他滨;膀胱灌注;膀胱非肌层浸润性尿路上皮癌;复发

[中图分类号] R737.1          [文献标识码] B          [文章编号] 1673-9701（2021）20-0062-04

lation chemotherapy on recurrence rate of non-muscle invasive bladder urothelium carcinoma

ZHANG Zhuo   ZHANG Wensheng   WAN Bin   LU Yigang   LI Xungang

Department Ⅰ of Urology Surgery， Jiujiang No.1 People′s Hospital in Jiangxi Province， Jiujiang   332000， China

[Abstract] Objective To explore the clinical efficacy of high-dose gemcitabine intravesical instillation chemotherapy on non-muscle invasive bladder urothelium carcinoma and its impacts on tumor recurrence. Methods A total of 60 patients with non-muscle invasive bladder urothelium carcinoma admitted to our hospital from September 2018 to September 2019 were divided into the control group and the observation group according to the random number table method. The control group was treated with conventional dose of gemcitabine chemotherapy，while the observation group was treated with high dose of gemcitabine intravesical instillation chemotherapy. The therapeutic efficacies， tumor markers，tumor recurrence time， tumor progression time， recurrence and complications of the two groups were compared. Results The objective remission rate of the observation group was 53.33%， which was higher than 30.00% of the control group， with statistically significant difference（P<0.05）. After treatment， NSE and CEA in the observation group were （1.33±0.11）ng/mL and （3.42±1.05）ng/mL respectively， which were both lower than those in the control group， with statistically significant differences（P<0.05）. In the observation group， the 1-year tumor recurrence rate was 10.00%， the tumor recurrence time was （17.31±2.62） months and the tumor progression time was （19.87±2.96） months. While in the control group， the 1-year tumor recurrence rate was 36.67%， the tumor recurrence time was （11.42±1.33） months and the tumor progression time was （17.54±1.71）months， with statistically significant differences（P<0.05）. There was no statistically significant differences in the incidence of dysuria， hematuria， frequent micturition and myelosuppression between two groups （P>0.05）. Conclusion The application of high-dose gemcitabine intravesical instillation chemotherapy on non-muscle invasive bladder urothelium carcinoma can improve the objective remission rate， reduce serum tumor markers， decrease tumor recurrence and prolong tumor recurrence time and progression time， which is worthy of clinical promotion and application.